Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC is a London‑based global medical technology company focused on two segments: Cardiopulmonary and Neuromodulation. It sells heart‑lung machines, oxygenators, perfusion systems, cannulae, and neuromodulation devices such as its VNS Therapy System, serving patients with drug‑resistant epilepsy, difficult‑to‑treat depression, and obstructive sleep apnea.
The company invests in R&D, including AI and software, and runs major clinical programs like the RECOVER depression study and the OSPREY trial for its aura6000 sleep apnea system. For 2025, 53% of net revenue came from the U.S., 19% from Europe, and 28% from the rest of the world. It reports extensive global regulatory, cybersecurity, trade, environmental, and compliance risks and highlights exposure to sanctions regimes through limited sales into Iran and other sanctioned markets.
As of December 31, 2025, LivaNova employed about 3,300 people in 34 countries and emphasizes culture, leadership development, and diversity initiatives as part of its human capital strategy.
LivaNova PLC reported strong fourth-quarter and full-year 2025 results while absorbing a large environmental charge and issuing 2026 guidance. Q4 revenue was $360.9 million, up 12.1% on a reported basis and 9.5% in constant currency, with double‑digit growth in both Cardiopulmonary and Neuromodulation.
For 2025, revenue reached $1.39 billion, rising 10.7% reported and 10.7% organically. GAAP diluted loss per share was $4.45 due largely to a $365.6 million SNIA environmental liability, while adjusted diluted earnings per share increased to $3.90 from $3.38.
The company guided 2026 constant-currency revenue growth between 6.0% and 7.0%, adjusted diluted earnings per share of $4.15 to $4.25, and adjusted free cash flow of $160 million to $180 million. LivaNova also gained significantly higher Medicare reimbursement for VNS Therapy DRE procedures and received U.S. FDA approval for its cloud-based digital health platform, supporting future Neuromodulation growth.
LivaNova PLC institutional holder PRIMECAP Management Co filed Amendment No. 8 to a Schedule 13G reporting its ownership stake. PRIMECAP reports beneficial ownership of 4,224,852 LivaNova shares, representing 7.74% of the class as of 12/31/2025.
The firm has sole voting power over 4,203,362 shares and sole dispositive power over 4,224,852 shares, with no shared voting or dispositive power. PRIMECAP certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of LivaNova.
LivaNova PLC’s ownership report shows several Millennium-affiliated entities holding more than five percent of its ordinary shares as of December 31, 2025. Integrated Core Strategies (US) LLC reports beneficial ownership of 3,065,717 shares, representing 5.6% of the class.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 3,484,082 shares, or 6.4% of the outstanding ordinary shares, through entities over which they have voting control and investment discretion. They certify the holdings are not for the purpose of changing or influencing control of LivaNova.
LivaNova PLC reported a leadership change in its legal function. On January 12, 2026, Senior Vice President, Chief Legal Officer, and Company Secretary Michael Hutchinson notified the company that he is resigning to pursue another opportunity. His last day with LivaNova will be January 26, 2026, creating a near-term transition period for the company’s legal and governance roles.
The company plans to retain an external search firm to begin the process of finding a new Chief Legal Officer, indicating that the board and management aim to bring in a successor through a structured, formal search.
LivaNova PLC officer reports RSU vesting and share withholding for taxes. The President, Cardiopulmonary of LivaNova PLC reported the vesting and settlement of 967 restricted stock units into ordinary shares on 12/15/2025 at an exercise price of $0. On the same date, 416 ordinary shares were disposed of through share withholding at a price of $63.06 to satisfy tax liabilities related to the vesting.
After these transactions, the officer beneficially owns 8,850 ordinary shares directly and 219 ordinary shares indirectly through a spouse. The RSUs were originally granted on December 15, 2023 under the Amended and Restated LivaNova PLC 2022 Incentive Award Plan and vested over a two-year schedule ending December 15, 2025.
LivaNova PLC director reported share activity related to vested restricted stock units. On December 15, 2025, 2,355 ordinary shares were acquired at $0 upon the exercise of previously granted RSUs under the LivaNova PLC 2015 Incentive Award Plan. On the same date, 269 shares were disposed of at $63.06 to cover tax liabilities, leaving 2,086 ordinary shares beneficially owned directly after these transactions.
The RSUs were originally granted on December 15, 2024 with a one-year vesting schedule and were subject to forfeiture before vesting under the plan and award agreement.
LivaNova PLC senior vice president, chief legal officer and company secretary reported routine equity activity related to restricted stock units. On December 15, 2025, 2,254 RSUs vested and were settled in ordinary shares at an exercise price of $0, increasing her directly held stake. On the same date, 1,122 ordinary shares were withheld at $63.06 per share to cover tax obligations, leaving 6,798 ordinary shares held directly after the transactions. The underlying RSUs were originally granted on December 15, 2022, under the LivaNova PLC 2022 Incentive Award Plan with a four-year vesting schedule, and 2,253 RSUs remain beneficially owned following this vesting event.
LivaNova PLC director reports small share sale in Form 4 filing. A company director sold 250 ordinary shares of LivaNova PLC (LIVN) on 11/18/2025 at a price of $53.94 per share. After this transaction, the director beneficially owns 6,232 ordinary shares, held directly. This filing is a routine disclosure of insider activity required under securities regulations and does not by itself describe any change in the company’s operations or strategy.